Galapagos announces PPAR-delta commercial license agreement with Hillcrest Therapeutics

Mechelen, Belgium; 1 February 2007 – Galapagos NV (Euronext & LSE: GLPG) announced today that it has signed an exclusive commercial license agreement with US-based Hillcrest Therapeutics, Inc., in which Hillcrest was granted worldwide rights to develop and commercialize the PPAR-delta technology in all fields.  PPAR-delta, a drug discovery program addressing diabetes and obesity, has reached the stage of candidate drug selection.  Hillcrest Therapeutics, located in San Diego, California, is a portfolio company of Paramount BioSciences LLC, a leading drug development and company capitalization firm.  Total contract value for Galapagos amounts to €770,000 in license fees, up to €27 million in potential milestones, undisclosed milestone payments in Hillcrest equity, and single digit royalties on commercial products arising from the program.
PPAR-delta[1] is a key regulator of the human body’s control of metabolism; as such, it is considered a valuable target for drug discovery in diabetes and obesity.  With the acquisition of Inpharmatica Ltd. on 5 December 2006, Galapagos obtained the downstream rights to the PPAR-delta program.  Inpharmatica applied its predictive drug discovery technologies to this internal R&D program, developed proprietary lead series, and reached candidate drug selection within 18 months of commencement.  Paramount BioSciences will be completing the development, clinical testing, and commercialization of this program.  Galapagos will have no further involvement in the execution of the development.
“Galapagos is pleased to realize the upside of this drug discovery program, which we obtained as a result of the Inpharmatica acquisition,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London AiM: GLPG) is a drug discovery company with clinical and pre-clinical programs in bone and joint diseases, cachexia, and menopausal hot flashes.  Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.  BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET[2] database products to select targets and compounds.  Galapagos currently employs 450 people and operates facilities in eight countries, with global headquarters in Mechelen, Belgium.  More information about Galapagos and BioFocus DPI can be found at

About Hillcrest Therapeutics and Paramount BioSciences
Hillcrest Therapeutics, Inc. is a development stage biopharmaceutical company focusing on cardiovascular and metabolic diseases.  Founded in 2006, it is a portfolio company of Paramount BioSciences, a preeminent drug development and company capitalization firm, which provides its portfolio companies with a wide-range of professional and financial support services.  More information can be found at
Galapagos NV                                                               
Dr Andre Hoekema
Senior Vice President Corporate Development
Tel: +31 65 151 7933
Paramount BioSciences LLC
Tara Crosson
Chief Marketing Officer
Tel:  +1 212 554 4351
This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

[1] PPAR-delta is the acronym for Peroxisome Proliferator Activated Receptor, a nuclear receptor that responds to fatty acids.
[2] ADMET is the acronym for Absorption, Distribution, Metabolism, Excretion and Toxicity: meeting parameters against these four criteria is critical to the success of a pharmaceutical compound as a drug.